Evidence map›Paper›PMID 31375704›Full record

ArticleScientific reports2019

Molecular integration of the anti-tropomyosin compound ATM-3507 into the coiled coil overlap region of the cancer-associated Tpm3.1.

Miro Janco, Michael J Rynkiewicz, Liang Li, Jeff Hook, Eleanor Eiffe, Anita Ghosh, Till Böcking, William J Lehman, Edna C Hardeman, Peter W Gunning

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Alterations of actin in aging.Journal of cell science · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Research Advances in the Role of the Tropomyosin Family in Cancer.International journal of molecular sciences · 2023
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. CRISPR-Based Activation of Endogenous Expression ofFrontiers in cell and developmental biology · 2021
    Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Miro JancoSchool of Medical Sciences, University of New South Wales Sydney, Sydney, NSW, 2052, Australia.
Michael J RynkiewiczDepartment of Physiology & Biophysics, Boston University School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA.
Liang LiSchool of Medical Sciences, University of New South Wales Sydney, Sydney, NSW, 2052, Australia.
Jeff HookSchool of Medical Sciences, University of New South Wales Sydney, Sydney, NSW, 2052, Australia.
Eleanor EiffeSchool of Medical Sciences, University of New South Wales Sydney, Sydney, NSW, 2052, Australia.
Anita GhoshDepartment of Physiology & Biophysics, Boston University School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA.
Till BöckingSingle Molecule Science and ARC Centre of Excellence in Advanced Molecular Imaging, University of New South Wales Sydney, Sydney, NSW, 2052, Australia.
William J LehmanDepartment of Physiology & Biophysics, Boston University School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA.
Edna C HardemanSchool of Medical Sciences, University of New South Wales Sydney, Sydney, NSW, 2052, Australia.ORCID http://orcid.org/0000-0003-1649-7712
Peter W GunningSchool of Medical Sciences, University of New South Wales Sydney, Sydney, NSW, 2052, Australia. p.gunning@unsw.edu.au.
UNSW Sydney · AUBoston University · US

Funding

Case Center for Synchrotron BiosciencesP30EB009998 · NIBIB · CASE WESTERN RESERVE UNIVERSITY · PI CHANCE, MARK R · 2009 to 2018
$8.4M
THIN FILAMENTS AND VERTEBRATE SMOOTH MUSCLE CONTRACTIONR01HL036153 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI William J Lehman · 1986 to 2026
$6.5M
NHLBI NIH HHS R01 HL036153NIBIB NIH HHS P30 EB009998
6 · The paper itself

Abstract

Tropomyosins (Tpm) determine the functional capacity of actin filaments in an isoform-specific manner. The primary isoform in cancer cells is Tpm3.1 and compounds that target Tpm3.1 show promising results as anti-cancer agents both in vivo and in vitro. We have determined the molecular mechanism of interaction of the lead compound ATM-3507 with Tpm3.1-containing actin filaments. When present during co-polymerization of Tpm3.1 with actin,

Indexed as

Actin CytoskeletonAntineoplastic AgentsCircular DichroismCrystallography, X-RayHumansMolecular Dynamics SimulationNeoplasmsProtein Conformation, alpha-HelicalProtein DomainsProtein IsoformsProtein MultimerizationRecombinant ProteinsStructure-Activity RelationshipThermodynamicsTropomyosinAntineoplastic AgentsProtein IsoformsRecombinant ProteinsTPM3 protein, humanTropomyosin

Identifiers

PMID31375704
PMCPMC6677793
OpenAlexW2964775954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.